Role of adipokins and intestinal microbiota in the developing of biliary tract’s inflammation in obesity (review of literature)
The article studies the role of adipokines and intestinal microbiota in the development of inflammation in the biliary tract in obesity by collecting data from previous studies and meta-analyzes from 2016 to 2020. An important pathophysiological role of inflammatory diseases of the biliary tract has been shown in the initiation of functional disorders of other organs and systems, leading in the future to serious diseases such as diabetes mellitus and obesity. Obesity is associated with an increase amount of adipocytes, which are directly linked to the development of diabetes, hypertension, and cardiovascular disease. The role of biomarkers of lipid metabolism, proinflammatory cytokines in the development of obesity has been disclosed in more detail, and also have been described modern pathogenetic links in the development of inflammatory processes in obesity, including the important role of the intestinal microbiota in the development of obesity. Early studies have been shown that low variety of gut microbiota are very closely associated with the development of a chronic inflammatory process of the biliary tract.
Abdulghani Sh., Efremova O.A., Chernobai P.E. 2021. Role of adipokins and intestinal microbiota in the developing of biliary tract’s inflammation in obesity (review of literature). Challenges in modern medicine. 44 (1): 28–37 (in Russian)
While nobody left any comments to this publication.
You can be first.
Belenkov Yu.N., Privalova Ye.V., Kaplunova V.Yu., Zektser V.Yu., Vinogradova N.N., Il'gisonis I.S., Shakar'yants G.A., Kozhevnikova M.V., Lishuta A.S. 2018. Metabolicheskiy sindrom: istoriya razvitiya, osnovnyye metody diagnostiki [Metabolic syndrome: History of development, main diagnostic criteria]. Ratsional'naya Farmakoterapiya v Kardiologii; 14 (5): 757–764. DOI: 10.20996/1819-6446-2018-14-5-757-764.
Gusova Z.R., Dzantiyeva Ye.O., Khripun I.A. 2015. Immunologicheskiye aspekty ozhireniya [Rational pharmacotherapy in cardiology] Al'manakh klinicheskoy meditsiny. Fevral'; Spets. vypusk. 1: 30–35.
Efremova O.A., Kamyshnikova L.A., Nikitin V.M., Lipunova E.A. 2014. Paralleli lipidnogo obmena i gipergomocisteinemii u bol'nyh s IBS i metabolicheskim sindromom [Parallels of lipid metabolism and hyperhomocysteinemia in patients with coronary artery disease and metabolic syndrome]. Nauchnyj rezul'tat. Serija: Medicina i farmacija. 1 (1): 48–52.
Sycheva N.L., Faustov L.A. 2017. Jendokrinnyj komponent rannej onkologicheskoj patologii pri jeksperimental'nom rake kishechnika кишечника [Endocrine component of early oncological pathology in experimental bowel cancer]. Nauchnyj rezul'tat. Serija: Medicina i farmacija. 3 (1): 15–23.
Yissachar N., Zhou Y., Ung L., Lai N.Y., Mohan J.F., Ehrlicher A., Weitz D.A., Kasper D.L., Chiu I.M., Mathis D., Benoist Ch. 2017. An Intestinal organ culture system uncovers a role for the nervous system in microbe-immune crosstalk. Cell. 168: 1135–1148.
Amin M.N., Hussain M.S., Sarwar M.S., Moghal M.M.R., Das A., Hossain M.Z., Chowdhury J.A., Millat M.S., Islam M.S. 2020. How the association between obesity and inflammation may lead to insulin resistance and cancer. Diabetes Metab. Syndr. Clin. Res. Rev. 2019, 13, 1213–1224. Molecules, 25, 1337 13 of 14.
B.I. Simanenkov, S.V. Tikhonov, I.G. Ilyashevich, A.V. Ledovaya, V.V. Makienko, N.V. Fedorov. 2017. Epidemiology, social aspects and pathogenesis of obesity. Bulletin of the North-West State Medical University. 9 (1): 21–27.
Blume F., Liu Y.C., Thiel D., Deska J. 2016. Chemoenzymatic total synthesis of (+)-& (−)-cis-osmundalactone. J. Mol. Catal. B Enzym. 134: 280–284.
Filippis De.F., Pellegrini N., Vannini L., Jeffery I.B., Storia La A., Laghi L., Serrazanetti I.D., Cagno D.R., Ferrocino I., Lazzi C., Turroni S., Cocolin L., Brigidi P., Neviani E., Gobbetti M., O'Toole W.P., Ercolini D. 2016. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut. 65: 1812–1821.
Fukui H. 2016. Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation? Inflammation Dis. 1: 135–145. doi: 10.1159/000447252.
Giampaoli S., Vannucchi S. 2016. Obesity and diabetes, a global problem: What does recent data tell us? Ig. E Sanita Pubblica, 72: 561–570.
Global report on diabetes. World Health Organization. France. 2016: 86. Available at: https://www.who.int/publications/list/ru/.
Griffin N.W., Ahern Ph.P., Cheng J., Heath A.C., Ilkayeva O., Newgard Ch.B., Fontana L., Gordon J.I. 2017. Prior Dietary Practices and Connections to a Human Gut Microbial Metacommunity Alter Responses to Diet Interventions. Cell. Host. Microbe; 21: 84–96.
Hopkins B., Goncalves M., Cantley L. 2016. Obesity and cancer mechanisms: cancer metabolism. Clin. Oncol. 34: 4277–83.
Kamitakahara H., Okayama T., Agusta A., Tobimatsu Y., Takano T. 2019. Two-dimensional NMR analysis of Angiopteris evecta rhizome and improved extraction method for angiopteroside. Phytochem. Anal. 30: 95–100.
Lamichhane R., Kim S.G., Kang S., Lee K.H., Pandeya P.R., Jung H.J. 2017. Exploration of underlying mechanism of anti-adipogenic activity of sulfuretin. Biol. Pharm. Bull., 40: 1366–1373.
Lamichhane R., Pandeya P.R., Lee K.H., Kim S.-G., Kandel D.R., Jung, H.-J. 2019. Angiopteris helferiana, a fern with great potential medicinal value: Antiadipogenic, anti-inflammatory, and anti-diabetic activity. Pharmacogn. Mag., 15: 423.
Lee B.H., Choi S.-H., Kim H.-J., Jung S.-W., Hwang S.H., Pyo M.K., Rhim H., Kim H.-C., Kim H.K., Lee S.-M. 2016. Differential effects of quercetin and quercetin glycosides on human α7 nicotinic acetylcholine receptor-mediated ion currents. Biomol. Ther. 24: 410.
Ligibel J., Wollins D. 2016. American Society of Clinical Oncology Obesity Initiative: rationale, progress, and future directions. Clin. Oncol. 34: 4256–60.
Lohmann A., Goodwin P., Chlebowski R. 2016. Association of obesity-related metabolic disruptions with cancer risk and outcome. Clin. Oncol. 34: 4249–255.
Ott S.J., Waetzig G.H., Rehman A., Moltzau-Anderson J., Bharti R., Grasis J.A. , Cassidy L., Tholey A., Fickenscher H., Seegert D., Rosenstiel Ph., Schreiber S. 2017. Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients with Clostridium difficile infection. Gastroenterology. 152: 799–811. e7.
Perry R.J., Peng L., Barry N.A., Cline G.W., Zhang D., Cardone R.L., Petersen K.F., Kibbey R.G., Goodman A.L., Shulman G.I. 2016. Acetate mediates a microbiome–brain–b-cell axis to promote metabolic syndrome. Nature. 534: 213–217.
Plovier H., Everard A., Druart C., Depommier C., Hul M.V., Geurts L., Chilloux J., Ottman N., Duparc Th., Lichtenstein L., Myridakis A., Delzenne N.M., Klievink J., Bhattacharjee A., Ark Kees C.H. van der, Aalvink S., Martinez L.O., Dumas M-E., Maiter D., Loumaye A., Hermans M.P., Thissen J.-P., Belzer C., Vos W.M. de, Cani P.D. 2017. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat. Med. 23: 107–113.
Saville S., Ouwehand A. Immune Impacts of Probiotics, Prebiotics and Synbiotics. International Probiotics Association (IPA) Education and Communications Committee. Available at: http://internationalprobiotics. org/immune/ [Accessed 10 August 2020].
Scheithauer T.P.M., Dallinga-Thie G.M., Vos M. de, Nieuwdorp M., Raalte D.H. 2016. Causality of small and large intestinal microbiota in weight regulation and insulin resistance. Molec Metab. 5: 759–770.
Sender R., Fuchs S., Milo R. 2016. Are We really vastly outnumbered? revisiting the ratio of bacterial to host cells in humans. Cell. 164: 337–340.
Shlomai N.O., Deshpande G., Rao S., Patole S. 2016. Type 2 diabetes mellitus and cancer: the role of pharmacotherapy. Clin. Oncol. 34: 4261–69.
WHO official site. Obesity and overweight. 2016. Available at: https:// www.who.int/endchildhood-obesity/publications/echo-report/ru/.
Yang L., Chen J.-H., Jie L., Wu Q., Xu T., Zhang H., Liu Q.-H., Yang H.-K. Obesity and other cancers. Clin. Oncol. 2016; 34: 4231–37.